ATE90363T1 - Lectine, die beta-d-galactosid binden. - Google Patents

Lectine, die beta-d-galactosid binden.

Info

Publication number
ATE90363T1
ATE90363T1 AT88907006T AT88907006T ATE90363T1 AT E90363 T1 ATE90363 T1 AT E90363T1 AT 88907006 T AT88907006 T AT 88907006T AT 88907006 T AT88907006 T AT 88907006T AT E90363 T1 ATE90363 T1 AT E90363T1
Authority
AT
Austria
Prior art keywords
galactoside
lectins
sequence
bind beta
amino acids
Prior art date
Application number
AT88907006T
Other languages
English (en)
Inventor
Arthur Donny Strosberg
Vivian Teichberg
Original Assignee
Ideon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideon Corp filed Critical Ideon Corp
Application granted granted Critical
Publication of ATE90363T1 publication Critical patent/ATE90363T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726Lectins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT88907006T 1987-07-21 1988-07-18 Lectine, die beta-d-galactosid binden. ATE90363T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8710288A FR2618439B1 (fr) 1987-07-21 1987-07-21 Sequences d'amino-acides reproduisant au moins en partie la sequence des lectines animales et humaines, leurs procedes d'obtention, leurs applications diagnostiques et therapeutiques
EP88907006A EP0368920B1 (de) 1987-07-21 1988-07-18 Lectine, die beta-d-galactosid binden
PCT/FR1988/000370 WO1989000581A1 (fr) 1987-07-21 1988-07-18 Lectines fixant le beta-d-galactoside

Publications (1)

Publication Number Publication Date
ATE90363T1 true ATE90363T1 (de) 1993-06-15

Family

ID=9353362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88907006T ATE90363T1 (de) 1987-07-21 1988-07-18 Lectine, die beta-d-galactosid binden.

Country Status (7)

Country Link
EP (1) EP0368920B1 (de)
JP (1) JPH03502446A (de)
AT (1) ATE90363T1 (de)
AU (1) AU616195B2 (de)
DE (1) DE3881698T2 (de)
FR (1) FR2618439B1 (de)
WO (1) WO1989000581A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693760A (en) * 1988-04-14 1997-12-02 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using HL-60 related lectins
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
FR2741883B1 (fr) * 1995-12-05 1998-02-20 Ass Pour Le Dev De La Biothera Composes possedant des proprietes lectiniques, et leurs applications biologiques
CN105916878A (zh) * 2013-07-24 2016-08-31 丹娜法伯癌症研究院 抗半乳糖凝集素1的单克隆抗体及其片段

Also Published As

Publication number Publication date
WO1989000581A1 (fr) 1989-01-26
AU2121488A (en) 1989-02-13
DE3881698T2 (de) 1993-11-25
AU616195B2 (en) 1991-10-24
EP0368920A1 (de) 1990-05-23
EP0368920B1 (de) 1993-06-09
FR2618439A1 (fr) 1989-01-27
FR2618439B1 (fr) 1990-05-25
DE3881698D1 (de) 1993-07-15
JPH03502446A (ja) 1991-06-06

Similar Documents

Publication Publication Date Title
NL7904144A (nl) Vetzuurpreparaten ter behandeling en voorkomen van thrombo-embolie.
AU2080988A (en) Esters of 13-trans-retinoic acid
NO960120D0 (no) ECF dobbelkontrast
FI912703A7 (fi) Oleellinen rasvahappokäsittely
ES527027A0 (es) Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas
IE871203L (en) Formulations containing unsaturated fatty acids
ATE96651T1 (de) Kosmetisches praeparat.
FR2499414B1 (fr) Production d'anticorps proteiniques humains
FI910853A7 (fi) Vektoreita ja yhdisteitä humaaniproteiini-C:n tsymogeenimuotojen ilmentämiseksi
ES493313A0 (es) Procedimiento para la preparacion de nuevas amidas de acidoscarboxilicos
DE3468021D1 (en) Imidazol-2-yl mercapto alkanoic acids, process for producing the same and pharmaceutical preparations containing the same
FI851508A7 (fi) Syklopropaaniaminohappojen ja peptidien synteesi.
DK0386451T3 (da) Oxiderede diphenylheteroalkaner, fremgangsmåde til fremstilling heraf og anvendelsen af disse
ATE90363T1 (de) Lectine, die beta-d-galactosid binden.
FR2355807A1 (fr) Derives d'acides isophtalamiques iodes et agents de contraste qui en contiennent
ATE353019T1 (de) Stereoisomere von fettsäureanalogen zur diagnostischen bildgebung
MX166685B (es) Proceso para la preparacion de alcanosulfonamidas y arenosulfonamidas
PT92187A (pt) Processo para a preparacao de neoglicoproteinas e de agentes de diagnostico que as contem
ES512583A0 (es) "procedimiento para la mejora de la amplificacion y de la expresion de vectores hibridos".
ES501886A0 (es) Procedimiento para la preparacion de nuevas amidas de acidoscarboxilicos
IT7951108A0 (it) Procedimento per la preparazione di cloridrati di amminoacidi e biclori drati di diamminoacidi
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
ATE37873T1 (de) Verfahren zur herstellung optisch aktiver 1,4dihydropyridine.
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.
EP0948361A4 (de) Spinresonanz kontrastmittel für das blut

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee